Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention Study
NCT ID: NCT07339761
Last Updated: 2026-01-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
30 participants
INTERVENTIONAL
2026-01-01
2028-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The treatment of bladder cancer is a multimodal and multidisciplinary discipline. Low-risk non-muscle-invasive bladder cancer (NMIBC) is treated by transurethral resection of the bladder (TURB) alone, while recurrent intermediate- and high-risk NMIBC undergo a combination of TURB and adjuvant intravesical instillation therapy. For patients with muscle-invasive bladder cancer (MIBC) and specific high-risk NMIBC cases, the first-line treatment option is radical cystectomy with urinary diversion, with or without neoadjuvant chemotherapy.
These treatment modalities are known to have a negative impact on sexual function, and studies in both men and women demonstrate profound impairments in sexual function, intimacy, and body image after treatment. Among men, erectile and ejaculatory dysfunction are prevalent for this patient group and frequently associated with diminished sexual satisfaction and body-image concerns. Likewise, women experience loss of sexual desire, orgasmic disorders, dyspareunia, and vaginal dryness following cystectomy.
A targeted literature search further identified no contemporary sexology-focused interventional or feasibility trials specifically in bladder cancer (neither MIBC or NMIBC). Existing evidence on the topic is largely descriptive or addresses non-sexological rehabilitation, demonstrating a evidence gap\[1\].
Qualitative research has also explored informational and psychosocial needs among bladder cancer patients, revealing limited communication about sexual health and unmet needs for professional support. Such studies provide valuable insight into patient experiences but have not yet translated this knowledge into the development of structured, sexological interventions.
Evidence from other cancer populations demonstrates that counselling and psychoeducational programmes addressing intimacy and sexuality are both feasible and beneficial, suggesting that similar interventions could be adapted for bladder cancer care.
To develop a relevant and acceptable intervention, it is essential to understand how patients themselves perceive their sexual health challenges, informational needs, and preferences for professional support regarding sexual health.
This project therefore consists of two sequential sub-studies:
* Study 1a (Development phase): A qualitative, exploratory study to develop a sexological intervention with patient and clinician involvement.
* Study 1b (Feasibility phase): A one-armed feasibility trial assessing the implementation and acceptability of the intervention among patients with muscle-invasive bladder cancer (MIBC).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sexual Function in Patients Suspected of Non-muscle Invasive Bladder Cancer
NCT02381912
Supporting Sexual Recovery in Women With Bladder Cancer
NCT07091565
Recovery Support for Bladder Cancer Patients and Caregivers
NCT04055311
Prognostic Biomarkers in Patients With Urothelial Carcinoma
NCT04872036
Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG
NCT05672615
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SEQUENTIAL
* Study 1b (Feasibility phase): A one-armed feasibility trial assessing the implementation and acceptability of the intervention among patients with muscle-invasive bladder cancer (MIBC).
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention arm (study 1b)
Sexological Support
Results from Study 1a will inform the development and refinement of the intervention to be tested in the feasibility phase (Study 1b).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sexological Support
Results from Study 1a will inform the development and refinement of the intervention to be tested in the feasibility phase (Study 1b).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Non-muscle-invasive bladder cancer treated with transurethral resection of the bladder (TUR-B)
2. Non-muscle-invasive bladder cancer treated with TUR-B and subsequent intravesical instillation therapy with chemotherapy or immunotherapy
3. Muscle-invasive bladder cancer treated with cystectomy (removal of the bladder)
* The participant has experienced changes and/or difficulties in sexual function related to the cancer diagnosis and/or its treatment
* The participant speaks and understands Danish
* The participant is aged 18 years or older
* The participant has read and understood the oral and written study information
* The participant has provided written informed consent
* The participant is diagnosed with Muscle-invasive bladder cancer treated with cystectomy (removal of the bladder)
* The participant speaks and understands Danish
* The participant is aged 18 years or older
* The participant has read and understood the oral and written study information
* The participant has provided written informed consent
Exclusion Criteria
* The participant has a history of breast cancer
* The participant has a history of other cancers located in the pelvic region, including rectal cancer, sarcomas, uterine cancer, cervical cancer, ovarian cancer, prostate cancer, or penile cancer
* The participant has a history of breast cancer
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Aarhus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Urology, Aarhus University Hospital
Aarhus, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DUAUHSPICE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.